News
MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are ... of action, or "MoA" to Novo's drug candidate ...
Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...
6h
HealthDay on MSNGLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With DiabetesFor patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...
A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...
Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...
glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms, according to a study ...
Share on Pinterest A new study shows GLP-1 drugs liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers. Carsten Snejbjerg/Bloomberg via Getty Images ...
Consider safety when combining GLP-1 medications with preexisting digestive health conditions. GLP-1 medications are prescribed to lower blood sugar levels in people with type 2 diabetes.
GLP-1 drugs are increasingly used to treat obesity in adults. They can also be used in children from the age of 12 and clinical trials have shown children lose 5-16% of their body weight after a ...
Hosted on MSN22d
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric SurgeryThe researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...
Semaglutide medications work by increasing the levels of a hormone called GLP-1 (glucagon-like peptide 1), a satiety signal that slows digestion and makes us feel full. These drugs also ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results